2023-03-07 09:41:03 ET
- Abbott ( NYSE: ABT ) announced Tuesday that the FDA cleared what could be the first commercially available blood-based laboratory test in the U.S. for traumatic brain injury (TBI), also known as concussion.
- The test, which runs on the company’s Alinity i laboratory instrument, can help doctors evaluate patients with mild TBI, ruling out the need for unnecessary CT scans and reducing the hospital wait time for patients.
- Abbott ( ABT ) said that the FDA nod is expected to widen the use of TBI testing in the U.S. as Alinity i instrument is commonly used in hospitals and laboratories.
- The Alinity i TBI lab test is designed to measure two plasma biomarkers linked to brain injury and gives results in 18 minutes.
- The regulatory clearance complements the company’s i-STAT TBI Plasma test, which the FDA greenlighted in 2021 as the first rapid blood test for concussion.
- Read: Seeking Alpha contributor Enterprising Investors upgraded Abbott ( ABT ) to Strong Buy from Buy, citing its recent acquisition of Cardiovascular Systems ( CSII ) for $890M, as announced in February.
For further details see:
Abbott wins FDA nod for blood-based concussion test